Journal Article
. 2014 Aug; 21(5):1127-38.
doi: 10.1158/1078-0432.CCR-14-1339.

Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies

Min Dai 1 Yuen Yee Yip 1 Ingegerd Hellstrom 1 Karl Erik Hellstrom 2 
Affiliations
  • PMID: 25142145
  •     54 References
  •     27 citations

Abstract

Purpose: Immunomodulatory mAbs can treat cancer, but cures are rare except for small tumors. Our objective was to explore whether the therapeutic window increases by combining mAbs with different modes of action and injecting them into tumors.

Experimental Design: Combinations of mAbs to CD137/PD-1/CTLA-4 or CD137/PD-1/CTLA-4/CD19 were administrated intratumorally to mice with syngeneic tumors (B16 and SW1 melanoma, TC1 lung carcinoma), including tumors with a mean surface of approximately 80 mm(2). Survival and tumor growth were assessed. Immunologic responses were evaluated using flow cytometry and qRT-PCR.

Results: More than 50% of tumor-bearing mice had complete regression and long-term survival after tumor injection with mAbs recognizing CD137/PD-1/CTLA-4/CD19 with similar responses in three models. Intratumoral injection was more efficacious than intraperitoneal injection in causing rejection also of untreated tumors in the same mice. The three-mAb combination could also induce regression, but was less efficacious. There were few side effects, and therapy-resistant tumors were not observed. Transplanted tumor cells rapidly caused a Th2 response with increased CD19 cells. Successful therapy shifted this response to the Th1 phenotype with decreased CD19 cells and increased numbers of long-term memory CD8 effector cells and T cells making IFNγ and TNFα.

Conclusions: Intratumoral injection of mAbs recognizing CD137/PD-1/CTLA-4/CD19 can eradicate established tumors and reverse a Th2 response with tumor-associated CD19 cells to Th1 immunity, whereas a combination lacking anti-CD19 is less effective. There are several human cancers for which a similar approach may provide clinical benefit.

Inhibition of TGFbeta1 makes nonimmunogenic tumor cells effective for therapeutic vaccination.
Pu Liu, Jade Jaffar, +3 authors, Karl Erik Hellström.
J Immunother, 2009 Feb 27; 32(3). PMID: 19242377
Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Marieke F Fransen, Marjolein Sluijter, +2 authors, Cornelis J M Melief.
Clin Cancer Res, 2011 Mar 11; 17(8). PMID: 21389097
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Asís Palazón, Iván Martínez-Forero, +11 authors, Ignacio Melero.
Cancer Discov, 2012 Jun 22; 2(7). PMID: 22719018
Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.
Min Dai, Huafeng Wei, +5 authors, Karl Erik Hellstrom.
J Immunother, 2013 Apr 23; 36(4). PMID: 23603859    Free PMC article.
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.
Aurélien Marabelle, Holbrook Kohrt, Ronald Levy.
Clin Cancer Res, 2013 Aug 24; 19(19). PMID: 23965900    Free PMC article.
Interactions of tumor cells with dendritic cells: balancing immunity and tolerance.
M V Dhodapkar, K M Dhodapkar, A K Palucka.
Cell Death Differ, 2007 Oct 20; 15(1). PMID: 17948027    Free PMC article.
Review.
Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy.
Chenghong Lei, Pu Liu, +7 authors, Karl Erik Hellstrom.
J Am Chem Soc, 2010 May 04; 132(20). PMID: 20433206    Free PMC article.
Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.
Shilin Yang, Yi Yang, +6 authors, Karl Erik Hellstrom.
Proc Natl Acad Sci U S A, 2004 Mar 31; 101(14). PMID: 15051893    Free PMC article.
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
Paolo A Ascierto, Ester Simeone, +2 authors, Ignacio Melero.
Semin Oncol, 2010 Nov 16; 37(5). PMID: 21074066
Highly Cited. Review.
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.
L Chen, S Ashe, +5 authors, P S Linsley.
Cell, 1992 Dec 24; 71(7). PMID: 1335364
Highly Cited.
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Robert D Schreiber, Lloyd J Old, Mark J Smyth.
Science, 2011 Mar 26; 331(6024). PMID: 21436444
Highly Cited. Review.
CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer.
I Hellstrom, J A Ledbetter, +6 authors, K E Hellstrom.
Proc Natl Acad Sci U S A, 2001 May 24; 98(12). PMID: 11371607    Free PMC article.
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
Karin E de Visser, Lidiya V Korets, Lisa M Coussens.
Cancer Cell, 2005 May 17; 7(5). PMID: 15894262
Highly Cited.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Cancer immunotherapy: moving beyond current vaccines.
Steven A Rosenberg, James C Yang, Nicholas P Restifo.
Nat Med, 2004 Sep 02; 10(9). PMID: 15340416    Free PMC article.
Highly Cited.
Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance.
S Ferrone, F M Marincola.
Immunol Today, 1995 Oct 01; 16(10). PMID: 7576053
Highly Cited. Review.
Tumor antigens recognized by T lymphocytes.
T Boon, J C Cerottini, +2 authors, A Van Pel.
Annu Rev Immunol, 1994 Jan 01; 12. PMID: 8011285
Highly Cited. Review.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.
Yi Yang, Shilin Yang, +6 authors, Karl Erik Hellström.
Cancer Res, 2007 Mar 03; 67(5). PMID: 17332366
Immunostimulatory monoclonal antibodies for cancer therapy.
Ignacio Melero, Sandra Hervas-Stubbs, +2 authors, Lieping Chen.
Nat Rev Cancer, 2007 Jan 26; 7(2). PMID: 17251916
Highly Cited. Review.
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Göran Jönsson, Christian Busch, +6 authors, Per Eystein Lønning.
Clin Cancer Res, 2010 May 13; 16(13). PMID: 20460471
Highly Cited.
IDO activates regulatory T cells and blocks their conversion into Th17-like T cells.
Babak Baban, Phillip R Chandler, +4 authors, Andrew L Mellor.
J Immunol, 2009 Jul 29; 183(4). PMID: 19635913    Free PMC article.
Highly Cited.
A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth.
Frank T Wen, Ronald A Thisted, Donald A Rowley, Hans Schreiber.
Oncoimmunology, 2012 Jun 22; 1(2). PMID: 22720238    Free PMC article.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Shari Pilon-Thomas, Amy Mackay, Nasreen Vohra, James J Mulé.
J Immunol, 2010 Mar 03; 184(7). PMID: 20194714    Free PMC article.
The role of the CD28 receptor during T cell responses to antigen.
P S Linsley, J A Ledbetter.
Annu Rev Immunol, 1993 Jan 01; 11. PMID: 8386518
Highly Cited. Review.
Immunosuppressive networks in the tumour environment and their therapeutic relevance.
Weiping Zou.
Nat Rev Cancer, 2005 Mar 19; 5(4). PMID: 15776005
Highly Cited. Review.
FcRgamma activation regulates inflammation-associated squamous carcinogenesis.
Pauline Andreu, Magnus Johansson, +11 authors, Lisa M Coussens.
Cancer Cell, 2010 Feb 09; 17(2). PMID: 20138013    Free PMC article.
Highly Cited.
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Kim Margolin, Marc S Ernstoff, +12 authors, F Stephen Hodi.
Lancet Oncol, 2012 Mar 30; 13(5). PMID: 22456429
Highly Cited.
Breakthrough of the year 2013. Cancer immunotherapy.
Jennifer Couzin-Frankel.
Science, 2013 Dec 21; 342(6165). PMID: 24357284
Highly Cited.
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
Jérôme Galon, Helen K Angell, Davide Bedognetti, Francesco M Marincola.
Immunity, 2013 Jul 31; 39(1). PMID: 23890060
Highly Cited. Review.
Inflammation and cancer.
Lisa M Coussens, Zena Werb.
Nature, 2002 Dec 20; 420(6917). PMID: 12490959    Free PMC article.
Highly Cited. Review.
Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.
Qinghua Feng, Huafeng Wei, +5 authors, Karl Erik Hellstrom.
Gynecol Oncol, 2012 Jul 26; 127(2). PMID: 22828962    Free PMC article.
Paradoxical roles of the immune system during cancer development.
Karin E de Visser, Alexandra Eichten, Lisa M Coussens.
Nat Rev Cancer, 2006 Jan 07; 6(1). PMID: 16397525
Highly Cited. Review.
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation.
Babak Baban, Anna M Hansen, +5 authors, Andrew L Mellor.
Int Immunol, 2005 Jun 22; 17(7). PMID: 15967784
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Brendan D Curti, Magdalena Kovacsovics-Bankowski, +20 authors, Andrew D Weinberg.
Cancer Res, 2013 Nov 02; 73(24). PMID: 24177180    Free PMC article.
Highly Cited.
Administration of cyclophosphamide changes the immune profile of tumor-bearing mice.
Pu Liu, Jade Jaffar, Ingegerd Hellstrom, Karl Erik Hellstrom.
J Immunother, 2009 Dec 03; 33(1). PMID: 19952956    Free PMC article.
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.
David G DeNardo, Lisa M Coussens.
Breast Cancer Res, 2007 Aug 21; 9(4). PMID: 17705880    Free PMC article.
Highly Cited. Review.
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.
I Melero, W W Shuford, +5 authors, L Chen.
Nat Med, 1997 Jun 01; 3(6). PMID: 9176498
Highly Cited.
Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.
Huafeng Wei, Likun Zhao, +8 authors, Yajun Guo.
PLoS One, 2013 Dec 25; 8(12). PMID: 24367702    Free PMC article.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.
Andrea Schietinger, Mary Philip, +2 authors, Hans Schreiber.
J Exp Med, 2010 Oct 06; 207(11). PMID: 20921286    Free PMC article.
Co-stimulation in T cell responses.
C A Chambers, J P Allison.
Curr Opin Immunol, 1997 Jun 01; 9(3). PMID: 9203422
Review.
Cellular immunity against tumor antigens.
K E Hellström, I Hellström.
Adv Cancer Res, 1969 Jan 01; 12. PMID: 4898911
Highly Cited. Review.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman.
Immunity, 2013 Jul 31; 39(1). PMID: 23890059
Highly Cited. Review.
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.
H Dong, G Zhu, K Tamada, L Chen.
Nat Med, 1999 Dec 02; 5(12). PMID: 10581077
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.
David J DiLillo, Koichi Yanaba, Thomas F Tedder.
J Immunol, 2010 Mar 03; 184(7). PMID: 20194720    Free PMC article.
Highly Cited.
Creating immune privilege: active local suppression that benefits friends, but protects foes.
Andrew L Mellor, David H Munn.
Nat Rev Immunol, 2007 Dec 08; 8(1). PMID: 18064049
Highly Cited. Review.
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
L Gorelik, R A Flavell.
Nat Med, 2001 Oct 09; 7(10). PMID: 11590434
Highly Cited.
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Aizea Morales-Kastresana, Miguel F Sanmamed, +12 authors, Ignacio Melero.
Clin Cancer Res, 2013 Sep 14; 19(22). PMID: 24030703
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Curr Opin Immunol, 2012 Jan 13; 24(2). PMID: 22236695    Free PMC article.
Highly Cited. Review.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Immunomodulatory antibody therapy of cancer: the closer, the better.
Roxana S Dronca, Haidong Dong.
Clin Cancer Res, 2014 Oct 30; 21(5). PMID: 25351746    Free PMC article.
Classification of current anticancer immunotherapies.
Lorenzo Galluzzi, Erika Vacchelli, +85 authors, Guido Kroemer.
Oncotarget, 2014 Dec 30; 5(24). PMID: 25537519    Free PMC article.
Highly Cited. Review.
Immune Mechanisms Are Major Players in Cancer.
Karl Erik Hellstrom, Ingegerd Hellstrom.
Clin Cancer Res, 2015 Apr 24; 21(16). PMID: 25904750    Free PMC article.
Inhibition of Tumor Growth and Immunomodulatory Effects of Flavonoids and Scutebarbatines of Scutellaria barbata D. Don in Lewis-Bearing C57BL/6 Mice.
Tao Gong, Chun-Fei Wang, +7 authors, Shen-Lin Liu.
Evid Based Complement Alternat Med, 2015 Jun 13; 2015. PMID: 26064167    Free PMC article.
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Aitziber Buqué, Norma Bloy, +12 authors, Lorenzo Galluzzi.
Oncoimmunology, 2015 Jul 03; 4(4). PMID: 26137403    Free PMC article.
Review.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Ignacio Melero, David M Berman, +3 authors, John Haanen.
Nat Rev Cancer, 2015 Jul 25; 15(8). PMID: 26205340
Highly Cited. Review.
CD137-CRDI is not necessary in the role of contacting its natural ligand.
Ling Yi, Zhuohong Yan, +3 authors, Hongtao Zhang.
Immunol Cell Biol, 2016 Jul 20; 95(1). PMID: 27430526
Basis for molecular diagnostics and immunotherapy for esophageal cancer.
Joe Abdo, Devendra K Agrawal, Sumeet K Mittal.
Expert Rev Anticancer Ther, 2016 Nov 15; 17(1). PMID: 27838937    Free PMC article.
Review.
Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.
Nina Deppisch, Peter Ruf, +2 authors, Ralph Mocikat.
Oncotarget, 2016 Dec 15; 8(3). PMID: 27966460    Free PMC article.
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs.
Aditya Arra, Holger Lingel, +6 authors, Monika C Brunner-Weinzierl.
Oncoimmunology, 2017 Mar 28; 6(2). PMID: 28344884    Free PMC article.
Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
Nicholas A Taylor, Sarah C Vick, +10 authors, Jonathan S Serody.
J Clin Invest, 2017 Aug 22; 127(9). PMID: 28825599    Free PMC article.
Highly Cited.
TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models.
Ismail M Meraz, Mourad Majidi, +8 authors, Jack A Roth.
Cancer Immunol Res, 2018 Jan 18; 6(2). PMID: 29339375    Free PMC article.
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Aurélie Durgeau, Yasemin Virk, Stéphanie Corgnac, Fathia Mami-Chouaib.
Front Immunol, 2018 Feb 07; 9. PMID: 29403496    Free PMC article.
Highly Cited. Review.
Tumor Regression and Cure Depends on Sustained Th1 Responses.
Min Dai, Ingegerd Hellstrom, +2 authors, Karl Erik Hellstrom.
J Immunother, 2018 Jun 19; 41(8). PMID: 29912725    Free PMC article.
Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes.
Raffaella Sabatino, Serafina Battistelli, Mauro Magnani, Luigia Rossi.
Drug Deliv Transl Res, 2018 Jul 18; 8(5). PMID: 30014237
Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade.
Netonia Marshall, Keino Hutchinson, +7 authors, Joshua D Brody.
Cancer Discov, 2019 Aug 04; 9(11). PMID: 31375522    Free PMC article.
Immunotherapy with Monoclonal Antibodies in Lung Cancer of Mice: Oxidative Stress and Other Biological Events.
Jun Tang, Daniel Ramis-Cabrer, Xuejie Wang, Esther Barreiro.
Cancers (Basel), 2019 Sep 07; 11(9). PMID: 31487876    Free PMC article.
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes.
Yu-Li Chen, Han-Wei Lin, +4 authors, Wen-Fang Cheng.
J Immunother Cancer, 2019 Nov 23; 7(1). PMID: 31753019    Free PMC article.
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.
Ronit Mazor, Emily King, Ira Pastan.
Cell Immunol, 2018 Sep 15; 334. PMID: 30213644    Free PMC article.
Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization.
Hae Lim Lee, Jeong Won Jang, +7 authors, Seung Kew Yoon.
Sci Rep, 2019 Mar 03; 9(1). PMID: 30824840    Free PMC article.
CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ.
Helin Wang, Zhuohong Yan, +7 authors, Shucai Zhang.
Thorac Cancer, 2019 Oct 19; 10(12). PMID: 31625289    Free PMC article.
CD137, an attractive candidate for the immunotherapy of lung cancer.
Lingyun Ye, Keyi Jia, +7 authors, Caicun Zhou.
Cancer Sci, 2020 Feb 20; 111(5). PMID: 32073704    Free PMC article.
Review.
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Jonathan P O Hebb, Adriane R Mosley, +4 authors, Dean W Felsher.
Cancer Immunol Immunother, 2017 Sep 15; 67(1). PMID: 28905118    Free PMC article.
Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4.
Lisa A Marshall, Sachie Marubayashi, +16 authors, Oezcan Talay.
J Immunother Cancer, 2020 Nov 28; 8(2). PMID: 33243932    Free PMC article.
Intratumoural administration and tumour tissue targeting of cancer immunotherapies.
Ignacio Melero, Eduardo Castanon, +2 authors, Aurelien Marabelle.
Nat Rev Clin Oncol, 2021 May 20; 18(9). PMID: 34006998    Free PMC article.
Review.
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
Alexa C Glencer, Jasmine M Wong, +7 authors, Michael J Campbell.
NPJ Breast Cancer, 2021 May 27; 7(1). PMID: 34035311    Free PMC article.
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
Iñaki Etxeberria, Elixabet Bolaños, +21 authors, Ignacio Melero.
Proc Natl Acad Sci U S A, 2021 Jun 27; 118(26). PMID: 34172583    Free PMC article.